23rd Annual Pharmaceutical and Medical Device Ethics and Compliance Congress
Gary Giampetruzzi, global chair of the Paul Hastings Life Sciences Practice, and BJ D’Avella, leader of the Paul Hastings Life Sciences Consulting Group, and Tara Giunta, co-chair of the Paul Hastings ESG & Business Human Rights Practice, will discuss key issues for compliance professionals at the upcoming 23rd Annual Pharmaceutical and Medical Device Ethics and Compliance Congress, October 24-26, in Washington, D.C.
Gary will speak on a panel entitled “CEOs and CCOs Sign on the Compliance Dotted Line — Now What?” with Glenn Leon, incoming fraud section chief, Criminal Division, U.S. Department of Justice, during the exclusive Chief Compliance Officer Roundtable on October 25th at 9:10 a.m.
BJ will participate in a mini summit entitled “You Finished Your Risk Assessment… Now What? Practical Approaches to Making Your Results Meaningful” with Christie Camelio, EQRx’s chief compliance and risk officer, and Olga Zinavenka, Endo International’s senior director of compliance investigations, on October 24th at 9:00 a.m.
Tara will speak on a mini summit panel entitled "Compliance Due Diligence in Mergers & Acquisitions” which will be moderated by Gildas Durand, a principal at EY and include panelists Shoshanna Clark, JD, Takeda’s head of USBU ethics & compliance operations, and Chris Corallo, Convatec’s compliance officer for North America, on October 25th at 10:00 a.m.
For more information and to register, visit the PCF website